Technical Analysis for COYA - Coya Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 7.24 | -0.55% | -0.04 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New Uptrend | Bullish | 0.00% | |
Volume Surge | Other | 0.00% | |
Wide Range Bar | Range Expansion | 0.00% | |
New 52 Week High | Strength | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Gapped Up | Strength | 0.00% | |
Overbought Stochastic | Strength | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Reversed from Down | about 19 hours ago |
Possible Pocket Pivot | about 19 hours ago |
Down 10% | about 22 hours ago |
Gap Up Closed | about 23 hours ago |
Reversed from Up | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/29/2023
Coya Therapeutics, Inc. Description
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Immunology Immune System Cell Therapy Metabolic Disease Amyotrophic Lateral Sclerosis T Cells Exosome Frontotemporal Dementia Medicinal Products
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.0 |
52 Week Low | 3.21 |
Average Volume | 47,128 |
200-Day Moving Average | 4.46 |
50-Day Moving Average | 4.95 |
20-Day Moving Average | 5.56 |
10-Day Moving Average | 6.04 |
Average True Range | 0.56 |
RSI (14) | 78.68 |
ADX | 26.89 |
+DI | 39.73 |
-DI | 6.94 |
Chandelier Exit (Long, 3 ATRs) | 6.31 |
Chandelier Exit (Short, 3 ATRs) | 6.09 |
Upper Bollinger Bands | 7.21 |
Lower Bollinger Band | 3.91 |
Percent B (%b) | 1.01 |
BandWidth | 59.23 |
MACD Line | 0.56 |
MACD Signal Line | 0.34 |
MACD Histogram | 0.2217 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 9.49 | ||||
Resistance 3 (R3) | 9.49 | 8.75 | 9.12 | ||
Resistance 2 (R2) | 8.75 | 8.17 | 8.75 | 8.99 | |
Resistance 1 (R1) | 7.99 | 7.82 | 7.62 | 7.99 | 8.86 |
Pivot Point | 7.25 | 7.25 | 7.06 | 7.25 | 7.25 |
Support 1 (S1) | 6.49 | 6.67 | 6.12 | 6.49 | 5.62 |
Support 2 (S2) | 5.75 | 6.32 | 5.75 | 5.49 | |
Support 3 (S3) | 4.99 | 5.75 | 5.37 | ||
Support 4 (S4) | 4.99 |